Supplementary Figure S4 from Addition of Ipatasertib to Dual Anti-HER2 Maintenance Therapy in HER2-Positive Metastatic Breast Tumors with PIK3CA Mutations: The Phase Ib SOLTI-1507 IPATHER Trial

2026 Open access

Read full text
Authors: Mafalda Oliveira, Eva Ciruelos, Guillermo Javierre Villacampa, Serafin M. Morales, Javier Salvador Bofill, Vanesa Quiroga, Joaquín Gavilá, Alexandra Cortegoso, Estela Vega, Fernando Henao, Sònia Servitja, Pablo Tolosa
+8 more Samyukta Chillara, Milana A. Bergamino, Fernando Salvador, Mariana Paes Dias, Juan Manuel Ferrero-Cafiero, Xavier González, Tomás Pascual, Cristina Saura
DOI: 10.1158/1078-0432.31248962
Cited by: 0

Abstract

Supplementary Figure S4 | Progression-free survival in the efficacy cohort since the initiation of first-line treatment for advanced disease (N = 16). Kaplan-Meier curve from the first-line treatment for metastatic breast cancer with trastuzumab plus pertuzumab plus chemotherapy. CI, confidence interval; NR; not reported; PFS, progression-free survival.

Fields of Study & Subjects

HER2/EGFR in Cancer Research Advanced Breast Cancer Therapies Lung Cancer Treatments and Mutations

Publication details

Publication date
4 February 2026
Language
EN